{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:02:43Z","timestamp":1761948163451,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13023-016-0450-y","type":"journal-article","created":{"date-parts":[[2016,5,22]],"date-time":"2016-05-22T21:07:50Z","timestamp":1463951270000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007\u201313) and prospective (2014\u201318) MIDAS sales data analysis"],"prefix":"10.1186","volume":"11","author":[{"given":"Victoria","family":"Divino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitch","family":"DeKoven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kleinrock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolin L.","family":"Wade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satyin","family":"Kaura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,21]]},"reference":[{"key":"450_CR1","unstructured":"Initial draft discussion document for a Canadian orphan drug regulatory framework. Health Canada, Office of Legislative and Regulatory Modernization. 2012. http:\/\/www.orpha.net\/national\/data\/CA-EN\/www\/uploads\/Initial-Draft-Discussion-Document-for-A-Canadian-Orphan-Drug--Regulatory-Framework.doc . Accessed 1 Dec 2015."},{"key":"450_CR2","unstructured":"Critchley W. Orphan drugs update \u2013 Canada. Presented at: FDLI Conference. 2014 May 14\u201315; Toronto, CA. http:\/\/www.fdli.org\/docs\/canadian\/critchley-fdli-may-14-2014.pdf?sfvrsn=0 . Accessed 1 Dec 2015."},{"key":"450_CR3","first-page":"e42","volume":"21","author":"DK Lee","year":"2014","unstructured":"Lee DK, Wong B. An Orphan Drug Framework (ODF) for Canada. J Popul Ther Clin Pharmacol. 2014;21:e42\u20136.","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"450_CR4","unstructured":"Electronic code of federal regulations title 21 food and drugs part 316 orphan drugs. U.S. Government Publishing Office. http:\/\/www.ecfr.gov\/cgi-bin\/text-idx?c=ecfr&SID=238362420de6b80c19b2a9c44b73a843&rgn=div6&view=text&node=21:5.0.1.1.6.3&idno=21 . Accessed 1 Dec 2015."},{"key":"450_CR5","unstructured":"Search orphan drug designations and approvals. U.S. Food and Drug Administration. www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/index.cfm . Accessed 28 Jul 2014."},{"key":"450_CR6","doi-asserted-by":"crossref","unstructured":"Gibson S, von Tigerstrom B. Orphan drug incentives in the pharmacogenomic context: policy responses in the US and Canada. J Law Biosci. 2015;2:263\u201391.","DOI":"10.1093\/jlb\/lsv013"},{"key":"450_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5582\/irdr.3.1","volume":"3","author":"AK Hall","year":"2014","unstructured":"Hall AK, Carlson MR. The current status of orphan drug development in Europe and the US. Intractable Rare Dis Res. 2014;3:1\u20137.","journal-title":"Intractable Rare Dis Res"},{"key":"450_CR8","unstructured":"Harper government takes action to help Canadians with rare diseases \u2013 launch of first ever Canadian framework to increase access to new treatments and information and Orphanet-Canada Portal \u2013 news release. Government of Canada. 2012. http:\/\/news.gc.ca\/web\/article-en.do?nid=698449 . Accessed 1 Dec 2015."},{"key":"450_CR9","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.healthpol.2015.01.009","volume":"119","author":"CM Douglas","year":"2015","unstructured":"Douglas CM, Wilcox E, Burgess M, Lynd LD. Why orphan drug coverage reimbursement decision-making needs patient and public involvement. Health Policy. 2015;119:588\u201396.","journal-title":"Health Policy"},{"key":"450_CR10","unstructured":"Notice of Compliance (NOC) database. Health Canada. 2014. http:\/\/www.hc-sc.gc.ca\/dhp-mps\/prodpharma\/notices-avis\/index-eng.php . Accessed 1 Jul 2014."},{"key":"450_CR11","unstructured":"IMS Midas. IMS Health. http:\/\/www.imshealth.com\/en\/solution-areas\/technology-and-applications\/offerings\/midas . Accessed 1 Dec 2015."},{"key":"450_CR12","unstructured":"Therapeutic categories outlook. Cowen and Company. 2014. http:\/\/www.cowen.com\/cowen-and-company\/ ."},{"key":"450_CR13","unstructured":"Consumer price index, historical summary (1995 to 2014). Statistics Canada. 2015. http:\/\/www.statcan.gc.ca\/tables-tableaux\/sum-som\/l01\/cst01\/econ46a-eng.htm . Accessed 11 Feb 2015."},{"key":"450_CR14","unstructured":"Market Prognosis 2014\u20132018, Canada. IMS Health. 2014. http:\/\/customerportal.imshealth.com\/portal\/site\/imsportal ."},{"key":"450_CR15","unstructured":"National Health Expenditure Trends, 1975 to 2013. Canadian Institute for Health Information (CIHI). 2013. https:\/\/secure.cihi.ca\/free_products\/NHEXTrendsReport_EN.pdf . Accessed 27 Jan 2016."},{"key":"450_CR16","unstructured":"Environmental scan \u2013 drugs for rare diseases: evolving trends in regulatory and health technology assessment perspectives. Canadian Agency for Drugs and Technologies in Health (CADTH). 2014. https:\/\/www.cadth.ca\/media\/pdf\/ES0281_RareDiseaseDrugs_es_e.pdf . Accessed 1 Dec 2015."},{"key":"450_CR17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1750-1172-9-22","volume":"9","author":"A Hutchings","year":"2014","unstructured":"Hutchings A, Schey C, Dutton R, Achana F, Antonov K. Estimating the budget impact of orphan drugs in Sweden and France 2013\u20132020. Orphanet J Rare Dis. 2014;9:22.","journal-title":"Orphanet J Rare Dis"},{"key":"450_CR18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13023-014-0154-0","volume":"9","author":"TA Kanters","year":"2014","unstructured":"Kanters TA, Steenhoek A, Hakkaart L. Orphan drugs expenditure in the Netherlands in the period 2006\u20132012. Orphanet J Rare Dis. 2014;9:154.","journal-title":"Orphanet J Rare Dis"},{"key":"450_CR19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3111\/13696998.2010.491427","volume":"13","author":"A Denis","year":"2010","unstructured":"Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. J Med Econ. 2010;13:295\u2013301.","journal-title":"J Med Econ"},{"key":"450_CR20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1750-1172-6-62","volume":"6","author":"C Schey","year":"2011","unstructured":"Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010\u20132020. Orphanet J Rare Dis. 2011;6:62.","journal-title":"Orphanet J Rare Dis"},{"key":"450_CR21","unstructured":"Facts about Generics. FDA. 2015. http:\/\/www.fda.gov\/drugs\/resourcesforyou\/consumers\/buyingusingmedicinesafely\/understandinggenericdrugs\/ucm167991.htm . Accessed 24 Mar 2016."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-016-0450-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T10:28:01Z","timestamp":1526639281000},"score":1,"resource":{"primary":{"URL":"http:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-016-0450-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,21]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["450"],"URL":"https:\/\/doi.org\/10.1186\/s13023-016-0450-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2016,5,21]]},"article-number":"68"}}